Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > latent GDF-8

latent GDF-8

Brief Information

Name:Growth/differentiation factor 8
Target Synonym:MSTN,GDF-8,GDF8,Growth Differentiation Factor 8,MSLHP,Myostatin,Growth/Differentiation Factor 8
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GD8-H5243 Human Human latent GDF-8 Protein, His Tag (MALS verified)
GD8-H5243-structure
GD8-H5243-sds

Part of Bioactivity data

GD8-H5243-ELISA
Human latent GDF-8, His Tag (Cat. No. ) MALS images

The purity of Human latent GDF-8, His Tag (Cat. No. GD8-H5243) is more than 90% and the molecular weight of this protein is around 85-95 kDa verified by SEC-MALS.

  • Background
    Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

latent GDF-8, GDF-8, Myostatin, GDF8, MSTN, Growth/differentiation factor 8

Background

Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Domagrozumab PF-6252616; PF-06252616 Phase 2 Clinical Pfizer Inc Muscular Dystrophy, Duchenne Details
AAV1-FS344 AAV1-FS344; AAV1-Follistatin Phase 2 Clinical Nationwide Children'S Hospital Myositis, Inclusion Body; Muscular Dystrophy, Duchenne Details
Trevogrumab REGN-1033; SAR-391786 Phase 2 Clinical Regeneron Pharmaceuticals Inc Myositis, Inclusion Body; Muscular Atrophy; Sarcopenia Details
Talditercept alfa (Bristol-Myers Squibb) RO-7239361; BMS-986089; RG-6206 Phase 3 Clinical Bristol-Myers Squibb Company Muscular Dystrophy, Duchenne Details
RG-6237 GYM-329; RG-70240; RG-6237 Phase 1 Clinical F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd Neuromuscular Diseases Details
Apitegromab SRK-015 Phase 3 Clinical Scholar Rock Spinal Muscular Atrophies of Childhood; Neuromuscular Manifestations; Muscular Atrophy; Neuromuscular Diseases; Muscular Atrophy, Spinal; Atrophy Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message